MedTrace Logo

Spectroscopic Imaging at 4T: A Drug Challenge Study

NCT01577706 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2017-04-04

Study results available
· View outcomes & findings →

Summary

An advanced technique for rapid magnetic resonance proton spectroscopic imaging (1H-MRSI) will be employed in a drug challenge study in healthy volunteers to spatially map and measure acute changes in the brain chemicals GABA, glutamate and glutamine after administration of a drug. Three condition will be tested in a double-blind fashion, i)depressant, ii)stimulant, iii)placebo. It is hypothesized that unique and reproducible spatial and directional metabolic response patterns will be observed, unique to each condition within the brain.

Conditions

  • AOD Effects and Consequences

Interventions

DRUG

Alprazolam

Alprazolam, gel-capsule, 1mg, single-dose, 1-day

DRUG

Dextroamphetamine

Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day

OTHER

Placebo

Placebo, gel-capsule, single-dose, 1-day

Sponsors & Collaborators

  • Mclean Hospital

    lead OTHER

Principal Investigators

  • John E Jensen, Ph.D. · Mclean Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01577706 on ClinicalTrials.gov